Table 1.
Minimal inhibitory concentration of plectasin against clinical isolates of MSSA and MRSA.
Table 2.
Combination actives of plectasin with ß-lactams, aminoglycosides and vancomycin.
Table 3.
Spa types of MSSA and MRSA isolates.
Fig 1.
Time-kill analysis showing the effects of plectation in combination with amoxicillin, gentamicin and neomycin against log phase MSSA and MRSA.
The peptide and antibiotics alone or each combined with plectasin were added to the log-phase cultures and CFU counts were carried out at different time points. Combination of plectasin (2 mg/L) and amoxicillin (1 mg/L or 512 mg/L) against MSSA (A) and MRSA (B). Combination of plectasin (2 mg/L) and gentamicin (0.25 and 0.5 mg/L) against MRSA (C) and MRSA (D). Combination of plectasin (2 mg/L) and neomycin (0.25 and 0.5 mg/L) against MSSA (E) and MRSA (F). Results shown are the mean of three independent experiments.
Fig 2.
Effects of plectasin in combination with amoxicillin and gentamicin against MSSA and MRSA in a murine thigh infection model and in a mouse peritoneal infection model.
In the murine thigh model, mice were infected with a strain of MSSA (t021) and a strain of MRSA (t032). Treatment was initiated 2 hours after infection with plectasin and amoxicillin against MSSA (A) and MRSA (B) and with plectasin and gentamicin against MSSA (C) and MRSA (D). Viability of the bacterial cells was determined from 6 mice for each group at 2, 4, 6 and 8 hours after treatment. In the mouse peritoneal infection model, mice were infected with the same strain of MSSA or MRSA. One hour after infection, treatment was initiated with plectasin and amoxicillin for MSSA (E) and for MRSA (F) and with plectasin and gentamicin for MSSA (G) and for MRSA (H). Bacterial counts in the peritoneal cavity were determined from 4 mice for each group at 2 and 5 hours post-treatment. The data have been repeated once.